Klaus Mendoza
Mar 25, 2016
Gilead ordered to pay Merck $200M for patent infringement
The federal jury in a patent trial has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing on patents for hepatitis C drugs.
The federal jury in a patent trial has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing on patents for hepatitis C drugs.